NEW DRUG APPLICATION

Ascendis Pharma · Navepegritide · TransCon CNP

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

SOURCE: Investors.AscendisPharma.com — Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years…

Read More Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
Achondroplasia · Tyra Biosciences · TYRA-300

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia

SOURCE: IR.TYRA.BIO CARLSBAD, Calif., Feb. 1, 2024 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR)…

Read More Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
Achondroplasia · BioMarin · Hypochondroplasia · Voxzogo

U.S. Food and Drug Administration Approves BioMarin’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

The following press release was obtained from BioMarin.com. To learn more about BioMarin, VOXZOGO®, vosorotide, and their other pipelines and research for achondroplasia and other skeletal dysplasias, click here. Expanded…

Read More U.S. Food and Drug Administration Approves BioMarin’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

translate ?